PharmaCyte Biotech annual revenue
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
PharmaCyte Biotech Revenue Growth & History (PMCB)
PharmaCyte Biotech reported $0 in revenue for fiscal 2026.
View full PharmaCyte Biotech company overviewPharmaCyte Biotech annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2026 | 2026-04-30 | $0 | $0 | — |
| 2025 | 2025-04-30 | $0 | $0 | — |
| 2024 | 2024-04-30 | $0 | $0 | — |
| 2023 | 2023-04-30 | $0 | $0 | — |
| 2022 | 2022-04-30 | $0 | $0 | — |
| 2021 | 2021-04-30 | $0 | $0 | — |
| 2020 | 2020-04-30 | $0 | $0 | — |
| 2019 | 2019-04-30 | $0 | $0 | — |
| 2018 | 2018-04-30 | $0 | $0 | — |
| 2017 | 2017-04-30 | $0 | $0 | — |
| 2016 | 2016-04-30 | $0 | $0 | — |
| 2015 | 2015-04-30 | $0 | $0 | — |
| 2014 | 2014-04-30 | $0 | −$12,160 | −100.00% |
| 2013 | 2013-04-30 | $12,160 | −$54,398 | −81.73% |
| 2012 | 2012-04-30 | $66,558 | −$59,439 | −47.17% |
| 2011 | 2011-04-30 | $125,997 | — | — |
PharmaCyte Biotech quarterly revenue
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
Q4.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q4 2026 | 2026-04-30 | $0 | $0 | — |
| Q3 2026 | 2026-01-31 | $0 | $0 | — |
| Q2 2026 | 2025-10-31 | $0 | $0 | — |
| Q1 2026 | 2025-07-31 | $0 | $0 | — |
| Q4 2025 | 2025-04-30 | $0 | $0 | — |
| Q3 2025 | 2025-01-31 | $0 | $0 | — |
| Q2 2025 | 2024-10-31 | $0 | $0 | — |
| Q1 2025 | 2024-07-31 | $0 | $0 | — |
| Q4 2024 | 2024-04-30 | $0 | $0 | — |
| Q3 2024 | 2024-01-31 | $0 | $0 | — |
| Q2 2024 | 2023-10-31 | $0 | $0 | — |
| Q1 2024 | 2023-07-31 | $0 | $0 | — |
| Q4 2023 | 2023-04-30 | $0 | $0 | — |
| Q3 2023 | 2023-01-31 | $0 | $0 | — |
| Q2 2023 | 2022-10-31 | $0 | $0 | — |
| Q1 2023 | 2022-07-31 | $0 | $0 | — |
| Q4 2022 | 2022-04-30 | $0 | $0 | — |
| Q3 2022 | 2022-01-31 | $0 | $0 | — |
| Q2 2022 | 2021-10-31 | $0 | $0 | — |
| Q1 2022 | 2021-07-31 | $0 | $0 | — |
| Q4 2021 | 2021-04-30 | $0 | $0 | — |
| Q3 2021 | 2021-01-31 | $0 | $0 | — |
| Q2 2021 | 2020-10-31 | $0 | $0 | — |
| Q1 2021 | 2020-07-31 | $0 | $0 | — |
| Q4 2020 | 2020-04-30 | $0 | $0 | — |
| Q3 2020 | 2020-01-31 | $0 | $0 | — |
| Q2 2020 | 2019-10-31 | $0 | $0 | — |
| Q1 2020 | 2019-07-31 | $0 | $0 | — |
| Q4 2019 | 2019-04-30 | $0 | $0 | — |
| Q3 2019 | 2019-01-31 | $0 | $0 | — |
| Q2 2019 | 2018-10-31 | $0 | $0 | — |
| Q1 2019 | 2018-07-31 | $0 | $0 | — |
| Q4 2018 | 2018-04-30 | $0 | $0 | — |
| Q3 2018 | 2018-01-31 | $0 | $0 | — |
| Q2 2018 | 2017-10-31 | $0 | $0 | — |
| Q1 2018 | 2017-07-31 | $0 | $0 | — |
| Q4 2017 | 2017-04-30 | $0 | $0 | — |
| Q3 2017 | 2017-01-31 | $0 | $0 | — |
| Q2 2017 | 2016-10-31 | $0 | $0 | — |
| Q1 2017 | 2016-07-31 | $0 | $0 | — |
| Q4 2016 | 2016-04-30 | $0 | $0 | — |
| Q3 2016 | 2016-01-31 | $0 | $0 | — |
| Q2 2016 | 2015-10-31 | $0 | $0 | — |
| Q1 2016 | 2015-07-31 | $0 | $0 | — |
| Q4 2015 | 2015-04-30 | $0 | $0 | — |
| Q3 2015 | 2015-01-31 | $0 | $0 | — |
| Q2 2015 | 2014-10-31 | $0 | $0 | — |
| Q1 2015 | 2014-07-31 | $0 | $0 | — |
| Q4 2014 | 2014-04-30 | $0 | $753 | +100.00% |
| Q3 2014 | 2014-01-31 | $0 | $0 | — |
| Q2 2014 | 2013-10-31 | $0 | −$6,287 | −100.00% |
| Q1 2014 | 2013-07-31 | $0 | −$6,626 | −100.00% |
| Q4 2013 | 2013-04-30 | −$753 | −$7,434 | −111.27% |
| Q3 2013 | 2013-01-31 | $0 | −$20,271 | −100.00% |
| Q2 2013 | 2012-10-31 | $6,287 | −$13,557 | −68.32% |
| Q1 2013 | 2012-07-31 | $6,626 | −$13,136 | −66.47% |
| Q4 2012 | 2012-04-30 | $6,681 | −$44,465 | −86.94% |
| Q3 2012 | 2012-01-31 | $20,271 | −$11,751 | −36.70% |
| Q2 2012 | 2011-10-31 | $19,844 | $3,975 | +25.05% |
| Q1 2012 | 2011-07-31 | $19,762 | −$7,198 | −26.70% |
| Q4 2011 | 2011-04-30 | $51,146 | — | — |
| Q3 2011 | 2011-01-31 | $32,022 | — | — |
| Q2 2011 | 2010-10-31 | $15,869 | — | — |
| Q1 2011 | 2010-07-31 | $26,960 | — | — |
PharmaCyte Biotech revenue growth trends
PharmaCyte Biotech's latest reported quarter, Q4 2026, generated $0 in revenue.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review PharmaCyte Biotech source filings ↗